Group 1 - The stock of InnoCare Pharma (09606) rose over 8%, reaching a new high of 459.8 HKD, with a trading volume of 271 million HKD [1] - The inclusion of InnoCare Pharma in the Hong Kong Stock Connect eligible securities list, effective from September 8, is expected to enhance the company's investor base and increase trading liquidity [1] - The company has been added to the Hang Seng Composite Index, indicating strong market recognition of its performance and value [1] Group 2 - InnoCare Pharma announced that its DB-1303/BNT323 has met the primary endpoint of progression-free survival (PFS) in a Phase III clinical trial for HER2-positive unresectable or metastatic breast cancer patients previously treated with trastuzumab and taxanes [2] - Following the interim analysis, the company plans to communicate with the National Medical Products Administration regarding the submission of a Biologics License Application (BLA) for DB-1303/BNT323 [2] - The company aims to accelerate the BLA process for DB-1303/BNT323 and deepen its global strategic collaboration with BioNTech for the drug's global development [2]
港股异动 | 映恩生物-B(09606)涨超8%破顶 近日获纳入港股通 HER2 ADC计划申报上市